TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10644567

Group type: EXPERIMENTAL
Intervention: CCK‐8 (2 ng. kg(‐1). min(‐1))
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 7
Study: 8876264

Group type: EXPERIMENTAL
Intervention: 20 mg/day prednisolone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1615179

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (5 mg) as one puff q.d.s. via inhaler
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6380212

Group type: EXPERIMENTAL
Intervention: Phenobarbital 12 mg/kg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Phenobarbital 4 mg/kg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Phenobarbital 8 mg/kg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (0 mg/kg)
Number of subjects: 43
Study: 30686386

Group type: EXPERIMENTAL
Intervention: THP peer-delivered (THPP) and enhanced usual care (EUC)
Number of subjects: 570

Group type: COMPARATOR
Intervention: EUC only
Number of subjects: 570
Study: 29161199

Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray (64 μg/mL) twice daily for 6 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 60
Study: 26891216

Group type: EXPERIMENTAL
Intervention: Black raspberry (750 mg/day)
Number of subjects: 51
Study: 24532599

Group type: EXPERIMENTAL
Intervention: PUFA-rich HF meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MUFA-rich HF meal
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SFA-rich HF meal
Number of subjects: 15
Study: 22992411

Group type: EXPERIMENTAL
Intervention: Stress perfusion cardiovascular magnetic resonance imaging (CMR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invasive coronary angiography and fractional flow reserve measurements
Number of subjects: 0
Study: 21062502

Group type: EXPERIMENTAL
Intervention: Symptom-defined GERD (mild heartburn and/or regurgitation ≥2 days/week, or moderate/severe heartburn and/or regurgitation ≥1 day/week)
Number of subjects: 16091

Group type: EXPERIMENTAL
Intervention: Troublesome reflux symptoms
Number of subjects: 16091

Group type: EXPERIMENTAL
Intervention: Reflux symptoms below the threshold for symptom-defined GERD
Number of subjects: 16091

Group type: EXPERIMENTAL
Intervention: Symptom-defined GERD
Number of subjects: 16091

Group type: EXPERIMENTAL
Intervention: Symptom frequency and severity approaching the threshold for symptom-defined GERD
Number of subjects: 16091
Study: 18080054

Group type: EXPERIMENTAL
Intervention: Continuous therapy (COT) with rabeprazole 20 mg
Number of subjects: 268

Group type: COMPARATOR
Intervention: On-demand therapy (ODT) with rabeprazole 20 mg
Number of subjects: 268
Study: 15620955

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA)
Number of subjects: 104
Study: 12168126

Group type: EXPERIMENTAL
Intervention: 0.5 ml line-clearing volume
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3.0 ml line-clearing volume
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4.0 ml line-clearing volume
Number of subjects: 12
Study: 11776799

Group type: EXPERIMENTAL
Intervention: CT + RT
Number of subjects: 64

Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 64
Study: 7876649

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (HM175) administered at 0, 1, and 6 months
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (HM175) administered at 0, 1, and 12 months
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (HM175)
Number of subjects: 151
Study: 2361813

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 362571

Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 30
Study: 31200952

Group type: EXPERIMENTAL
Intervention: Implementation support using a whole‐ward approach for advance care planning
Number of subjects: 0
Study: 28459402

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation guided by transpulmonary pressure (Ptp) of 20 cmH2O
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation guided by transpulmonary pressure (Ptp) of 10 cmH2O
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation guided by transpulmonary pressure (Ptp) of 15 cmH2O
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (ventilated by guidance of ARDSNet)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Duration of mechanical ventilation
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Length of ICU stay
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 28-day mortality
Number of subjects: 67
Study: 25567119

Group type: EXPERIMENTAL
Intervention: KD-287 (JE-VC)
Number of subjects: 205

Group type: COMPARATOR
Intervention: JEV-GCC (JE-MB)
Number of subjects: 205
Study: 23464715

Group type: EXPERIMENTAL
Intervention: Oral synbiotic (Agri-King Synbiotic, AKSB)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: AKSB
Number of subjects: 196
Study: 20890244

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg monthly) plus PDT
Number of subjects: 162

Group type: COMPARATOR
Intervention: PDT alone
Number of subjects: 162
Study: 19660610

Group type: EXPERIMENTAL
Intervention: Simvastatin plus Fenofibrate (20 mg simvastatin + 160 mg fenofibrate)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Simvastatin monotherapy (20 mg)
Number of subjects: 594
Study: 16750735

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Milrinone
Number of subjects: 30
Study: 14718691

Group type: EXPERIMENTAL
Intervention: Systematic screening with the Adverse Events Profile (AEP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care without the AEP
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Systematic screening with the AEP
Number of subjects: 62
Study: 10931799

Group type: EXPERIMENTAL
Intervention: Autopsy group with acute myocardial infarction (MI)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Patients with significant coronary artery disease (CAD)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Patients who died of myocardial failure
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Non-CAD patients
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Autopsied group with acute MI
Number of subjects: 171
Study: 9333106

Group type: EXPERIMENTAL
Intervention: Tolcapone 100 mg t.i.d.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tolcapone 200 mg t.i.d.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tolcapone 400 mg t.i.d.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tolcapone 800 mg t.i.d.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tolcapone (all dosages)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8489751

Group type: EXPERIMENTAL
Intervention: Levonova (20 micrograms levonorgestrel daily)
Number of subjects: 1821

Group type: COMPARATOR
Intervention: Cu-T IUDs
Number of subjects: 1821
Study: 2426932

Group type: EXPERIMENTAL
Intervention: Allylestrenol (AE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlormadinone acetate (CMA)
Number of subjects: 0
Study: 30642387

Group type: EXPERIMENTAL
Intervention: WELCOME-IdA intervention (dementia-specific case conferences)
Number of subjects: 6
Study: 28604115

Group type: EXPERIMENTAL
Intervention: xyloglucan-based nasal spray
Number of subjects: 40

Group type: COMPARATOR
Intervention: saline nasal spray
Number of subjects: 40
Study: 25888571

Group type: EXPERIMENTAL
Intervention: Symptomatic CVC-related thrombosis
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: White blood cell count >10.6 × 10^9/L
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Mean FVIII activity
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: PAI-1 >12.2 IU/mL
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: CVC-related infections
Number of subjects: 168
Study: 24021286

Group type: EXPERIMENTAL
Intervention: Nurse-led lifestyle counseling (five face-to-face sessions and telephone contact over one year)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard medical advice (control group)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Nurse-led lifestyle counseling
Number of subjects: 74
Study: 22776634

Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lurasidone 120 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lurasidone 160 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine extended-release 600 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lurasidone 40-160 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lurasidone 40-120 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lurasidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19820238

Group type: EXPERIMENTAL
Intervention: Fixed-dose regimens in RCTs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 18572996

Group type: EXPERIMENTAL
Intervention: Personal Initiative (PI) training program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard stress management program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 16097981

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NO donor)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control experimental series
Number of subjects: 10
Study: 11934658

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol combined with gestodene
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol combined with gestodene
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Piperazine, estrone sulfate in combination with norethisterone
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol and 1 mg norethisterone acetate
Number of subjects: 274

Group type: COMPARATOR
Intervention: Untreated women
Number of subjects: 274
Study: 9971865

Group type: EXPERIMENTAL
Intervention: Bed rest
Number of subjects: 183

Group type: COMPARATOR
Intervention: Watchful waiting (Control)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 183
Study: 7540071

Group type: EXPERIMENTAL
Intervention: FK506 alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: FK506 plus methylprednisolone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: FK506 plus methotrexate (MTX)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Transplant-related mortality
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1-year disease-free survival
Number of subjects: 18
Study: 2189248

Group type: EXPERIMENTAL
Intervention: Proguanil at 200 mg/d combined with sulphafurazole at 25 mg/kg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proguanil at 200 mg/d combined with sulphamethoxazole at 25 mg/kg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proguanil at 200 mg/d combined with sulphamethoxazole at 10 mg/kg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6769420

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 194
Study: 31502893

Group type: EXPERIMENTAL
Intervention: Aflibercept 2.0 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Ranibizumab 0.3 mg
Number of subjects: 2
Study: 31256092

Group type: EXPERIMENTAL
Intervention: Motor rehabilitation plus cognitive intervention (G1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motor rehabilitation only (G2)
Number of subjects: 0
Study: 28379056

Group type: EXPERIMENTAL
Intervention: 15-minute AL-TENS application
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 30-minute AL-TENS application
Number of subjects: 11

Group type: COMPARATOR
Intervention: Comparison of 15-minute vs 30-minute AL-TENS
Number of subjects: 11
Study: 25498838

Group type: EXPERIMENTAL
Intervention: SBRT plans established after September 2011
Number of subjects: 66

Group type: COMPARATOR
Intervention: SBRT plans established before September 2011
Number of subjects: 66
Study: 23966214

Group type: EXPERIMENTAL
Intervention: Practice-managed condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient-managed condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low SES practices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-to-high SES practices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard Dutch practice
Number of subjects: 0
Study: 21392600

Group type: EXPERIMENTAL
Intervention: Extended-release niacin
Number of subjects: 850

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 850
Study: 19151304

Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch solution
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 70
Study: 17264336

Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (CT) and radiotherapy (RT)
Number of subjects: 716

Group type: COMPARATOR
Intervention: Sequential chemotherapy (CT) followed by radiotherapy (RT)
Number of subjects: 716
Study: 15525879

Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Alfacalcidol (0.5 microg/day)
Number of subjects: 24
Study: 11292041

Group type: EXPERIMENTAL
Intervention: Closed kinetic chain resistance exercises (3 sessions per week for 4 weeks)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Open kinetic chain resistance exercises (3 sessions per week for 4 weeks)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Injured leg (both exercise groups)
Number of subjects: 37
Study: 9329641

Group type: EXPERIMENTAL
Intervention: 60 mg vitamin C/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 6 g vitamin C/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (both doses)
Number of subjects: 48
Study: 8172789

Group type: EXPERIMENTAL
Intervention: Epirubicin (100 mg/m2 every three weeks, escalating to a maximum of 140 mg/m2)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fluorouracil (500 mg/m2 days 1‐5 every three weeks, escalating to a maximum of 700 mg/m2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Epirubicin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fluorouracil
Number of subjects: 70
Study: 3359786

Group type: COMPARATOR
Intervention: Placebo with standardized breakfast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Standardized meal
Number of subjects: 12
Study: 29880257

Group type: EXPERIMENTAL
Intervention: KaempMax™ (100 mg daily for 30 days)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: KaempMax™
Number of subjects: 14
Study: 27537508

Group type: EXPERIMENTAL
Intervention: Turning Point
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 80
Study: 25239491

Group type: EXPERIMENTAL
Intervention: Bilateral intramuscular administration of cytokine‐mobilized CD133+ cells (50-400 million cells)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline injections, sham leukapheresis, and intramuscular injection of placebo buffered solution
Number of subjects: 10
Study: 22500703

Group type: EXPERIMENTAL
Intervention: Posturographic evaluation at home
Number of subjects: 35

Group type: COMPARATOR
Intervention: Posturographic evaluation in hospital
Number of subjects: 35
Study: 20601351

Group type: COMPARATOR
Intervention: Resource-based system
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Task-based system
Number of subjects: 75
Study: 18819393

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO) for 3 days (twice a day) using a monoplace chamber under pressures of 1.7‐1.9 ATA
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standardized treatment protocol (Control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 44
Study: 16204433

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12012623

Group type: EXPERIMENTAL
Intervention: Oral estradiol 4 mg/day (group A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Oral estradiol 6 mg/day (group B)
Number of subjects: 29
Study: 10631416

Group type: EXPERIMENTAL
Intervention: Paracetamol 2 g through a nasogastric tube
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rectal paracetamol 2 g
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard doses of paracetamol (6 g/day) on day 1 after cardiac surgery
Number of subjects: 20
Study: 8745039

Group type: EXPERIMENTAL
Intervention: 60 micrograms of DDAVP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 2401754

Group type: EXPERIMENTAL
Intervention: Ethanol at peak estimated blood alcohol concentration (Est.BAC) of 0.07 gm/dL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol at peak Est.BAC of 0.1 gm/dL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol at peak Est.BAC of 0.14 gm/dL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7272396

Group type: EXPERIMENTAL
Intervention: High need for power subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low need for power subjects
Number of subjects: 0
Study: 31833441

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (normal lung function)
Number of subjects: 90
Study: 30575239

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with irinotecan (60 mg/m2 on days 1 and 8) and nedaplatin (80 mg/m2 on day 1 of every 21‐day cycle) followed by radical hysterectomy and adjuvant chemotherapy.
Number of subjects: 32
Study: 28898131

Group type: EXPERIMENTAL
Intervention: New solid nodules < 4 mm
Number of subjects: 25002

Group type: EXPERIMENTAL
Intervention: New solid nodules 4 to < 6 mm
Number of subjects: 25002

Group type: EXPERIMENTAL
Intervention: New solid nodules 6 to < 8 mm
Number of subjects: 25002

Group type: EXPERIMENTAL
Intervention: New solid nodules ≥ 20 mm
Number of subjects: 25002

Group type: EXPERIMENTAL
Intervention: New solid nodules overall
Number of subjects: 25002

Group type: EXPERIMENTAL
Intervention: Cancers associated with new nodules
Number of subjects: 25002
Study: 25342648

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation
Number of subjects: 449

Group type: COMPARATOR
Intervention: High ligation and stripping
Number of subjects: 449

Group type: COMPARATOR
Intervention: High ligation/endovenous laser ablation
Number of subjects: 449
Study: 25087600

Group type: EXPERIMENTAL
Intervention: Vortioxetine (10-20 mg/day)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Agomelatine (25-50 mg/day)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Vortioxetine and Agomelatine
Number of subjects: 493
Study: 22079390

Group type: COMPARATOR
Intervention: Nutraceuticals (coenzyme Q(10), RRR‐α‐tocopherol, selenium aspartate, and L‐methionine) with cryotherapy for HPV warts
Number of subjects: 157

Group type: COMPARATOR
Intervention: Nutraceuticals (coenzyme Q(10), RRR‐α‐tocopherol, selenium aspartate, and L‐methionine) with acyclovir for herpes infections
Number of subjects: 157

Group type: COMPARATOR
Intervention: Nutraceuticals (coenzyme Q(10), RRR‐α‐tocopherol, selenium aspartate, and L‐methionine)
Number of subjects: 157
Study: 19671308

Group type: EXPERIMENTAL
Intervention: Glucagon injection
Number of subjects: 68

Group type: COMPARATOR
Intervention: Normal controls (NC)
Number of subjects: 68
Study: 17498005

Group type: EXPERIMENTAL
Intervention: KRN321 (darbepoetin alfa) administered at extended dose intervals (once per week or once every two weeks)
Number of subjects: 513

Group type: COMPARATOR
Intervention: rHuEPO (recombinant human erythropoietin)
Number of subjects: 513
Study: 15170885

Group type: EXPERIMENTAL
Intervention: 1 g/m2 MTX as a 24-hr infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 g/m2 MTX as a 24-hr infusion
Number of subjects: 30
Study: 11587466

Group type: COMPARATOR
Intervention: Classical SDD regimen (tobramycin 80 mg, polymyxin E 100 mg, amphotericin B 500 mg)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Modified SDD regimen with mupirocin (2% mupirocin ointment applied four times daily in nostrils and modified oral paste)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Classical SDD regimen
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Modified SDD regimen with mupirocin
Number of subjects: 223
Study: 9838776

Group type: EXPERIMENTAL
Intervention: Spray group
Number of subjects: 98

Group type: COMPARATOR
Intervention: Double layer group
Number of subjects: 98
Study: 7861710

Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normolipidemic subjects (cholesterol < 6.5 mmol/liter, triglycerides < 2.0 mmol/liter)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Hyperlipidemic subjects
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: All renal patients combined
Number of subjects: 53
Study: 2510275

Group type: EXPERIMENTAL
Intervention: Rioprostil, 300 micrograms q.d.s.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rioprostil, 100 micrograms q.d.s.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo q.d.s.
Number of subjects: 0
Study: 782468

Group type: EXPERIMENTAL
Intervention: sodium pentosan polysulphate/nicotinic acid combination (Compuron)
Number of subjects: 60
Study: 31395363

Group type: EXPERIMENTAL
Intervention: Integrative Positive Psychological Intervention for Depression (IPPI-D)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 128
Study: 28292340

Group type: EXPERIMENTAL
Intervention: Phentolamine mesylate (Oraverse)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 150